209 related articles for article (PubMed ID: 26469352)
1. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.
Gerke TA; Martin NE; Ding Z; Nuttall EJ; Stack EC; Giovannucci E; Lis RT; Stampfer MJ; Kantoff PW; Parmigiani G; Loda M; Mucci LA
Prostate; 2015 Dec; 75(16):1926-33. PubMed ID: 26469352
[TBL] [Abstract][Full Text] [Related]
2. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
[TBL] [Abstract][Full Text] [Related]
3. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.
Allott EH; Ebot EM; Stopsack KH; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Ahearn TU; Gerke TA; Downer MK; Rider JR; Freedland SJ; Lotan TL; Kantoff PW; Platz EA; Loda M; Stampfer MJ; Giovannucci E; Sweeney CJ; Finn SP; Mucci LA
Clin Cancer Res; 2020 Mar; 26(5):1086-1093. PubMed ID: 31754047
[TBL] [Abstract][Full Text] [Related]
4. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
6. miQ--a novel microRNA based diagnostic and prognostic tool for prostate cancer.
Larne O; Martens-Uzunova E; Hagman Z; Edsjö A; Lippolis G; den Berg MS; Bjartell A; Jenster G; Ceder Y
Int J Cancer; 2013 Jun; 132(12):2867-75. PubMed ID: 23184647
[TBL] [Abstract][Full Text] [Related]
7. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR.
Simper NB; Jones CL; MacLennan GT; Montironi R; Williamson SR; Osunkoya AO; Wang M; Zhang S; Grignon DJ; Eble JN; Tran T; Wang L; Baldrige LA; Cheng L
Hum Pathol; 2015 Jun; 46(6):805-12. PubMed ID: 25870120
[TBL] [Abstract][Full Text] [Related]
8. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer.
Mithal P; Allott E; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Sangale Z; Lanchbury JS; Stone S; Freedland SJ
Int J Urol; 2014 Dec; 21(12):1209-14. PubMed ID: 25099119
[TBL] [Abstract][Full Text] [Related]
9. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
10. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.
Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY
Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616
[TBL] [Abstract][Full Text] [Related]
11. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.
Zhao S; Geybels MS; Leonardson A; Rubicz R; Kolb S; Yan Q; Klotzle B; Bibikova M; Hurtado-Coll A; Troyer D; Lance R; Lin DW; Wright JL; Ostrander EA; Fan JB; Feng Z; Stanford JL
Clin Cancer Res; 2017 Jan; 23(1):311-319. PubMed ID: 27358489
[TBL] [Abstract][Full Text] [Related]
12. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.
Zu K; Martin NE; Fiorentino M; Flavin R; Lis RT; Sinnott JA; Finn S; Penney KL; Ma J; Fazli L; Gleave ME; Bismar TA; Stampfer MJ; Pollak MN; Loda M; Mucci LA; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):1984-93. PubMed ID: 23983239
[TBL] [Abstract][Full Text] [Related]
13. Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression.
Ahearn TU; Tchrakian N; Wilson KM; Lis R; Nuttall E; Sesso HD; Loda M; Giovannucci E; Mucci LA; Finn S; Shui IM
J Clin Endocrinol Metab; 2016 Jun; 101(6):2520-7. PubMed ID: 27115058
[TBL] [Abstract][Full Text] [Related]
14. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
[TBL] [Abstract][Full Text] [Related]
15. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
16. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.
Rubicz R; Zhao S; Wright JL; Coleman I; Grasso C; Geybels MS; Leonardson A; Kolb S; April C; Bibikova M; Troyer D; Lance R; Lin DW; Ostrander EA; Nelson PS; Fan JB; Feng Z; Stanford JL
Mol Oncol; 2017 Feb; 11(2):140-150. PubMed ID: 28145099
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
18. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
19. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome.
Kälin M; Cima I; Schiess R; Fankhauser N; Powles T; Wild P; Templeton A; Cerny T; Aebersold R; Krek W; Gillessen S
Eur Urol; 2011 Dec; 60(6):1235-43. PubMed ID: 21741162
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
Sinnott JA; Peisch SF; Tyekucheva S; Gerke T; Lis R; Rider JR; Fiorentino M; Stampfer MJ; Mucci LA; Loda M; Penney KL
Clin Cancer Res; 2017 Jan; 23(1):81-87. PubMed ID: 27663590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
